Maintenance of Antibody Response in Egyptian Healthcare Workers Vaccinated with ChAdOx1 nCoV-19 Vaccine during Delta and Omicron Variants Pandemic: A Prospective Study

Hammad, Noha M.; Kadry, Heba M.; Malek, Mai; Bahgat, Shereen Mohamed; Abdelsalam, Noha; Afifi, Amira Hamed Mohamed; Abo-Alella, Doaa

doi:10.3390/vaccines10101706

Cited by 3 publications

(10 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nearly two-thirds (64.8%) of the seronegative healthcare workers (HCWs) showed seroconversion rates of 81.8% and 93.3% after the first and second vaccination doses, respectively. 12 In consistent with Madhi et al 22 study in South Africa, ChAdOx1 nCoV-19 COVID-19 vaccine efficacy against B.1.351 variant was 10.4% (95% CI, −76.8 to 54.8). A two-dose regimen of the ChAdOx1 nCoV-19 vaccine did not show protection against mild-to-moderate COVID-19 due to the B.1.351 variant.…”

Section: Resultssupporting

confidence: 76%

“…One person with HIV died (unlikely related). As per Hammad et al, 12 safety report demonstrated that the most common adverse reactions were pain and malaise. No serious adverse event was reported.…”

Section: Resultsmentioning

confidence: 83%

“…A total of 13 studies were included in this systematic review (810,466 participants from Africa) and overall, 62.18% participants were female. From these included studies, the majority were conducted in South Africa except Zhang et al and Hammad et al; which were conducted in Morocco 11 and Egypt, 12 respectively. Five of the included studies were multinational trials.…”

Section: Resultsmentioning

confidence: 99%

“…Five of the included studies were multinational trials. Nine studies out of 13 were a randomized clinical trial (RCT) and the other included studies were a single-arm implementation trial, retrospective cohort study, prospective study and test negative case–control study by Takuva et al, 13 Zhang et al, 11 Hammad et al, 12 and Gray et al, 14 respectively. In all studies, the minimum participant age was 18 years except studies done by Thomas et al 15 in South Africa and Hammad et al 12 study in Egypt which were 12 and 20 years, respectively.…”

Section: Resultsmentioning

confidence: 99%

“…Nine studies out of 13 were a randomized clinical trial (RCT) and the other included studies were a single-arm implementation trial, retrospective cohort study, prospective study and test negative case-control study by Takuva et al, 13 Zhang et al, 11 Hammad et al, 12 and Gray et al, 14 respectively. In all studies, the minimum participant age was 18 years except studies done by Thomas et al 15 in South Africa and Hammad et al 12 study in Egypt which were 12 and 20 years, respectively. In the 13 included studies, different COVID-19 vaccines were used to assess and evaluate either the safety or efficacy to assess and evaluate both the safety and efficacy of COVID-19 vaccine; the vaccines used in the studies were SCB-2019 vaccine, BNT162b2 mRNA vaccine, Ad26.COV2.S Vaccine, a booster regimen of Ad26.COV2.S vaccine, NVX-CoV2373 vaccine, ChAdOx1 nCoV-19 vaccine and BBIBP-CorV vaccine.…”

Section: Characteristics Of the Included Studiesmentioning

confidence: 99%

See 4 more Smart Citations

Safety and Efficacy of COVID-19 Vaccine in Africa: Systematic Review

Mengstu,

Beyene Berha

2023

IDR

View full text Add to dashboard Cite

Background Coronavirus disease 2019 (COVID-19) pandemic scared the whole world at the end of 2019, which is a communicable respiratory disease caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). In South Africa and other African countries, the COVID-19 vaccines were subsequently approved for emergency use by the respective national regulatory authorities. There is a paucity of aggregated data that revealed the safety and efficacy of COVID-19 vaccines in Africa. Objective The aim of this systematic review was to synthesize the literature on the safety and efficacy of the COVID-19 vaccine which was given in Africa. Methods A systematic search was conducted on Science Direct, PubMed, EMBASE, Google Scholar, CINAHL, Cochrane Library, and direct Google searches. Only studies written in English and published articles from 2019 to October 30, 2022, which comprise nine randomized clinical trials (RCT), and four different studies including a single-arm implementation trials, prospective study, retrospective cohort study, and test-negative designs were included. Results A total of 13 studies were included which contain 810,466 participants from Africa. Of these, 62.18% of the participants were female. The efficacy of COVID-19 vaccine in Africa ranges from 41.7% to 100%. Moreover, vaccine efficacy against COVID-19 variants ranges from −5.7% to 100%. In general, systemic and local adverse events following vaccination in most trials were reported with a similar pattern between the placebo and vaccine groups. Out of the total reported adverse events, most of them were mild to moderate, whereas a few were serious. Conclusion Almost all current COVID‐19 vaccines appear to be safe for African study participants. Regarding efficacy, the protein subunit vaccine and mRNA vaccine exhibited high efficacy (100%) in this group of participants. However, Ad26. COV2.S and ChAdOx1 nCoV-19 COVID-19 vaccines are not effective against the delta variant and B.1.351 variant, respectively.

show abstract

Section: Resultssupporting

confidence: 76%

Section: Resultsmentioning

confidence: 83%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Characteristics Of the Included Studiesmentioning

confidence: 99%

See 3 more Smart Citations

Safety and Efficacy of COVID-19 Vaccine in Africa: Systematic Review

Mengstu,

Beyene Berha

2023

IDR

View full text Add to dashboard Cite

show abstract

A scoping review of active, participant centred, digital adverse events following immunization (AEFI) surveillance of WHO approved COVID-19 vaccines: A Canadian immunization Research Network study

Serhan,

Psihogios,

Kabir

et al. 2024

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

This scoping review examines the role of digital solutions in active, participant-centered surveillance of adverse events following initial release of COVID-19 vaccines. The goals of this paper were to examine the existing literature surrounding digital solutions and technology used for active, participant centered, AEFI surveillance of novel COVID-19 vaccines approved by WHO. This paper also aimed to identify gaps in literature surrounding digital, active, participant centered AEFI surveillance systems and to identify and describe the core components of active, participant centered, digital surveillance systems being used for post-market AEFI surveillance of WHO approved COVID-19 vaccines, with a focus on the digital solutions and technology being used, the type of AEFI detected, and the populations under surveillance. The findings highlight the need for customized surveillance systems based on local contexts and the lessons learned to improve future vaccine monitoring and pandemic preparedness.

show abstract

A Causal Inference of the Effect of Vaccination on COVID-19 Disease Severity and Need for Intensive Care Unit Admission Among Hospitalized Patients in an African Setting

Belayneh,

Leulseged,

Teklu

et al. 2023

Preprint

View full text Add to dashboard Cite

Background: The COVID-19 pandemic is a respiratory illness that has spread to over 210 countries and killed over 6 million people. There is no specific treatment for COVID-19, but vaccines have been developed that can help prevent severe illness and death. A number of studies have investigated the effect of vaccination on disease severity and outcome, and the findings indicate that vaccination is linked to a significant reduction in the risk of hospitalization, intensive care unit admission, and death from the disease. However, there is a scarcity of evidence in Africa in general, and no similar study has been conducted in Ethiopia yet. Therefore, the study aimed to assess the effect of vaccination on COVID-19 disease severity and need for Intensive Care Unit (ICU) admission among hospitalized patients at a private specialty clinic in Ethiopia. Methods: A retrospective cohort study was conducted among 126 patients with COVID-19, 41 vaccinated and 85 unvaccinated, who were hospitalized between September 2021 and May 2022. Data was summarized using frequency (percentage) and median (interquartile range). To compare the characteristics of the two groups, Chi-square/ Fisher's Exact and Mann Whitney U tests at p-value of ≤ 0.05 were used. To identify the effect of vaccination on COVID-19 disease severity, Marginal Structural Model (MSM) with inverse probability weighting (IPW) approach using robust poisson regression model was fitted and adjusted relative risk (ARR) and 95% CI for ARR were used for interpreting the result. Results: The cohort included groups that were fairly comparable in terms of their sociodemographic and clinical characteristics. More than half of the participants were older than 60 years (52.4%), were males (56.3%) and had one or more comorbid illness (52.4%). At admission 85 (67.5%) had severe disease and 11 (8.7%) progressed after hospitalization and required ICU admission, of which three unvaccinated cases died. From the final model, vaccination was found to be associated with a 62% decreased risk of developing severe COVID-19 disease if infected, compared to not getting vaccinated (ARR=0.38, 95% CI=0.23-0.65, p<0.0001). Conclusions: The study's findings support previous reports that vaccinated people are less likely to develop severe COVID-19 disease if infected with the virus, emphasizing the importance of continuing efforts to promote COVID-19 vaccination not only to safeguard individuals but also to confer community-level immunity.

show abstract

Maintenance of Antibody Response in Egyptian Healthcare Workers Vaccinated with ChAdOx1 nCoV-19 Vaccine during Delta and Omicron Variants Pandemic: A Prospective Study

Cited by 3 publications

References 63 publications

Safety and Efficacy of COVID-19 Vaccine in Africa: Systematic Review

Safety and Efficacy of COVID-19 Vaccine in Africa: Systematic Review

A scoping review of active, participant centred, digital adverse events following immunization (AEFI) surveillance of WHO approved COVID-19 vaccines: A Canadian immunization Research Network study

A Causal Inference of the Effect of Vaccination on COVID-19 Disease Severity and Need for Intensive Care Unit Admission Among Hospitalized Patients in an African Setting

Contact Info

Product

Resources

About